Andrea Discacciati
Overview
Explore the profile of Andrea Discacciati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Discacciati A, Abbadi A, Clements M, Annerstedt M, Carlsson S, Gronberg H, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39562218
Background And Objective: The use of blood-based risk prediction tools has been proposed to improve prostate cancer screening, but data on repeated screening are lacking. Our aim was to compare...
2.
Engel J, Eklund M, Jaderling F, Palsdottir T, Falagario U, Discacciati A, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39443223
Background And Objective: The optimal biopsy strategy in prostate cancer screening is unknown. This study aims to assess the diagnostic effects of omitting systematic biopsies in a screening cohort. Methods:...
3.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3381.
PMID: 39198712
No abstract available.
4.
De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, et al.
Nat Med
. 2024 Aug;
30(11):3291-3302.
PMID: 39164518
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian framework to evaluate efficacy within predefined biomarker signatures across systemic treatments. Prospective circulating tumor DNA and germline...
5.
Vigneswaran H, Eklund M, Discacciati A, Nordstrom T, Hubbard R, Perlis N, et al.
J Clin Oncol
. 2024 Jul;
42(32):3806-3816.
PMID: 39038251
Purpose: Asian, Black, and Hispanic men are underrepresented in prostate cancer (PCa) clinical trials. Few novel prostate cancer biomarkers have been validated in diverse cohorts. We aimed to determine if...
6.
Bellavia A, Melloni G, Park J, Discacciati A, Murphy S
Am J Epidemiol
. 2024 May;
193(8):1155-1160.
PMID: 38775274
Interaction analysis is a critical component of clinical and public health research and represents a key topic in precision health and medicine. In applied settings, however, interaction assessment is usually...
7.
Bjornebo L, Razdan S, Discacciati A, Palsdottir T, Aly M, Nordstrom T, et al.
J Natl Cancer Inst
. 2024 May;
116(9):1459-1465.
PMID: 38718219
Background: α1-Adrenergic receptor antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit tumor growth. This study evaluated the risk of...
8.
Bjornebo L, Discacciati A, Falagario U, Vigneswaran H, Jaderling F, Gronberg H, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e247131.
PMID: 38648061
Importance: Prostate cancer guidelines often recommend obtaining magnetic resonance imaging (MRI) before a biopsy, yet MRI access is limited. To date, no randomized clinical trial has compared the use of...
9.
Nordstrom T, Annerstedt M, Glaessgen A, Carlsson S, Clements M, Abbadi A, et al.
JAMA Netw Open
. 2024 Feb;
7(2):e2354577.
PMID: 38324313
Importance: Magnetic resonance imaging (MRI) has been proposed to enhance the benefit-to-harm ratio of prostate cancer screening, but data on repeated screening outcomes are lacking. Objective: To describe outcomes of...
10.
Hammarstrom M, Gabrielson M, Crippa A, Discacciati A, Eklund M, Lundholm C, et al.
Br J Cancer
. 2023 May;
129(1):61-71.
PMID: 37149701
Background: Adherence to adjuvant tamoxifen therapy is suboptimal, and acceptance of tamoxifen for primary prevention is poor. Published results indicate effect of low-dose tamoxifen therapy. Using questionnaire data from a...